Region — US. Neutral scientific reference — not offered for sale here.
Cart · 0
Set region
Vallydia
ExploreShopToolsJournalTrust
Explore  /  Niacinamide (Vitamin B3)
Research reference — not for sale

Niacinamide (Vitamin B3)

A
lead outcome
Topical: hyperpigmentation (melasma, PIH,…
grades vary by outcome ↓
Small molecule (non-peptide)
also called — nicotinamide · vitamin B3 · NAM · 3-pyridinecarboxamide · INCI: Niacinamide
skin appearance (cosmetic)barrier supporthyperpigmentation appearanceantioxidantsebum appearance

Niacinamide is a lawful cosmetic ingredient worldwide. Vallydia uses it in cosmetic serums at concentrations supported by clinical trials (2–10%) with appearance-only claims. Reference science below includes both topical cosmetic and higher-dose oral / medical uses; only topical cosmetic use is relevant to the sellable product.

In brief

Niacinamide (nicotinamide, vitamin B3) is one of the best-evidenced cosmetic active ingredients. Multiple independent controlled human trials show measurable improvement in skin appearance related to hyperpigmentation, barrier function (reduced TEWL), and — at higher concentrations — fine lines and sebum. Effect sizes are modest compared with prescription retinoids or hydroquinone, but tolerability is much better and it plays well with almost every other active. It is a cornerstone cosmetic ingredient, not a hero molecule.

Legal standing, by region
International
Lawful cosmetic ingredient

Topical Niacinamide is a lawful cosmetic ingredient globally, including EU (Regulation (EC) 1223/2009), UK, US, and Asia. CosIng-listed. No concentration ceiling in the EU cosmetic framework; consumer formulas typically use 2–10%. Not a controlled or restricted substance.

Evidence, by outcome
How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Topical: hyperpigmentation (melasma, PIH, age spots) at 2–5%
Smaller than hydroquinone in head-to-head trials; better tolerated; typically requires 8+ weeks of twice-daily use
Multiple double-blind, split-face, vehicle-controlled RCTs (Hakozaki 2002 n=18 and n=79 dose-response; Kimball 2010; 2005 sallowness split-face n=~200); recent 2025 narrative reviews confirm consistent effect · Measurable reduction of melanin transfer to keratinocytes; visible skin-tone improvement over 8–12 weeks
A
Barrier function / TEWL (2–5%)
Formulation and vehicle matter; mechanism robust in vitro and in vivo
Controlled trials showing measurable ceramide/free fatty acid synthesis increase and TEWL reduction; Kimball 10-week trial with 4% NAM + N-acetylglucosamine · Improved stratum corneum integrity, reduced water loss
A
Fine lines and appearance of photoaging (5–6%)
Smaller than tretinoin/retinoids; multi-active formulations make isolated effect hard to prove
RCT of 6% niacinamide formulation reporting ~15% fine-line reduction; JAAD split-face sallowness study · Modest visible improvement in appearance of fine lines and texture
B
Sebum/oiliness reduction (2–4%)
Effect modest; some trials mixed; regional variability (better in Asian studies)
Multiple controlled trials at 2% and 4% for 2–4 weeks · Measurable reduction in sebum excretion rate
B
Acne vulgaris (topical 4%)
Consumer skincare framing: use as appearance/comfort adjunct, not medicine
Randomized trials vs clindamycin 1%; comparable efficacy on inflammatory lesions · Reduction in inflammatory lesion count
B
Systemic / oral high-dose "anti-aging" claims
Systemic dosing outside cosmetic scope; do not conflate oral clinical data with topical serum claims
Small metabolic studies; oral NAM supplementation for photoprotection · Oral 500 mg BID reduced non-melanoma skin cancer incidence in ONTRAC trial; unrelated to cosmetic topical claims
D
Safety (topical)
Occasional mild flushing/tingling at higher concentrations; rare contact reactions; concentrations >10% not shown to add benefit
Decades of widespread cosmetic use; controlled trials · Generally well tolerated
—
Cosmetic claims boundary
✓ Allowed (appearance / feel)
  • for the appearance of a more even, brighter-looking complexion
  • helps improve the look of uneven skin tone
  • supports the appearance of a healthy skin barrier
  • for the look of smoother, more refined-looking skin
  • antioxidant
✕ Not allowed (medicinal)
  • treats melasma
  • treats hyperpigmentation
  • treats acne
  • inhibits melanogenesis
  • repairs the skin barrier
  • stimulates ceramide synthesis
  • reduces inflammation
  • anti-inflammatory
  • prevents skin cancer
  • reverses photoaging

The medicinal-sounding science stays in the reference section; product copy speaks only to appearance/feel (Reg 655/2013). Different fields, never merged.

Identity

a water-soluble amide form of vitamin B3 (pyridine-3-carboxamide). It is the biologically active form used by the body to synthesise NAD+ and NADP+ — coenzymes central to cellular energy metabolism, DNA repair, and hundreds of enzymatic reactions. In skincare it is applied topically as a small, stable, well-tolerated molecule.

Development & history

  • Recognised as an essential nutrient in the 1930s (as part of the vitamin B complex, curing pellagra).
  • Studied for cosmetic and dermatological uses since the 1970s.
  • Emerged as a mainstream cosmetic active in the early 2000s, driven by Procter & Gamble research (Hakozaki, Bissett) demonstrating measurable effects on pigmentation, barrier, and skin appearance.
  • Today it is one of the most-studied and most-used cosmetic ingredients, appearing in serums, moisturisers, sunscreens, and treatment products across every price tier.

Mechanism (as proposed)

a small hydrophilic molecule that penetrates the stratum corneum readily. In keratinocytes it acts as a precursor to NAD+/NADP+, supporting cellular energy and repair. Documented mechanisms relevant to skin appearance include: reduced melanosome transfer from melanocytes to keratinocytes (mechanism behind the pigmentation effect); increased synthesis of ceramides and free fatty acids in the stratum corneum (mechanism behind the barrier effect); modulation of sebaceous lipogenesis; and antioxidant activity through NAD+-dependent enzymes.

Sources — 6 cited
01Hakozaki T, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002; 147(1):20-31.
02Bissett DL, et al. Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin. Int J Cosmet Sci. 2004; 26(5):231-8.
03Kimball AB, et al. Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N-acetyl glucosamine. Br J Dermatol. 2010; 162(2):435-41.
04Marques C, et al. Mechanistic Basis and Clinical Evidence for the Applications of Nicotinamide (Niacinamide) to Control Skin Aging and Pigmentation. Antioxidants (Basel). 2021; PMC8389214.
05Sadler K, Kubiak K. Clinical Evaluation of Niacinamide in Hyperpigmentation and Barrier Repair. J Cosmo Tricho. 2025; 11:308.
06Topical Niacinamide in Daily Skincare: A 3-Week Real-World Cosmetic Study. Appl Sci. 2025; 15(17):9729.
Review status
Not yet reviewed

A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated 2026-07-07.

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
GHK-Cu (Copper Tripeptide-1)B
Peptide
Matrixyl (Palmitoyl Pentapeptide-4)B
Peptide
Argireline (Acetyl Hexapeptide-8)C
Peptide
Explore by goal
Skin & aesthetic →
Vallydia

A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.

Region — United States
ExploreRegisterCategoriesTrust & COAHow we grade
ShopCosmetic peptidesJournal
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.

Niacinamide (Vitamin B3) — evidence, uses & status · Vallydia